Ronald de Wit

6PUBLICATIONS
53CO-AUTHORS
Molecular targetsInstrumental methods (excl. immunological and bioassay methods)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.

Julie N Graff, Christopher J Hoimes, Winald R Gerritsen

|Dec 11, 2023
Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product.

Michiel Stevens, Anouk Mentink, Frank A W Coumans

|Nov 29, 2023
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.

Stefan A J Buck, Annelies Van Hemelryk, Corrina de Ridder

|Mar 05, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

Joaquim Bellmunt, Ronald de Wit, Yves Fradet

|Jan 18, 2022
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD.

Ronald de Wit, Stephen J Freedland, Stephane Oudard

|Oct 07, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells.

Maud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht

Pageof 1

Frequent Collaborators

1 joint publications

Hayri E Balcioglu

1 joint publications

Debbie G J Robbrecht

1 joint publications

Geert J L H van Leenders

1 joint publications

J Alberto Nakauma-González